Author/Authors :
Akbari, Azam Department of Pharmaceutics - Tehran University of Medical Sciences, Tehran, Iran , Akbarzadeh, Azim Department of Nanobiotechnology - Pasteur Institute of Iran, Tehran, Iran , Rafiee Tehrani, Morteza Department of Pharmaceutics - Tehran University of Medical Sciences, Tehran, Iran , Ahangari Cohan, Reza Department of Nanobiotechnology - Pasteur Institute of Iran, Tehran, Iran , Mozaffari Dehshiri, Alireza Resposible pharmacist office of Barij pharmaceutical company, Kashan, Iran , Memarzadeh, Mohammad Reza Medicinal plant research center of Barij pharmaceutical company, Kashan, Iran
Abstract :
Cancer is a fatal disease and relatively widespread in the world; Breast
cancer is the most prevalent cancer among women. Hydroxyurea (HU)
is a chemotherapy drug for the cure of cancer different types in patients,
for example breast cancer, but has several defects, for to remove these
problems in this study a nanoliposome (NL) suspension for Hydroxyurea
(HU) delivery in breast cancer cell therapy was developed.HU was
encapsulated into NLs. Size was measured by nanosizer. The release
of the liposomal formulation was assessed during 36 h. FTIR analysis
for liposomal Hydroxyurea and free Hydroxyurea was carried out. The
uptake capacity of the formulation was determined by transfection of
nanoliposomal hydroxyurea (NL-HU) in MDA-MB231 cells via flow
cytometer and fluorescence microscopy studies, the cytotoxicity of NLHU
and free HU was evaluated in cells. Size of NL-HU was 174nm,
HU encapsulation efficiencies in NLs was 81%. FTIR analysis showed
the stability of HU in the liposome and no improper interaction between
liposome and HU, release after 36h depicted sustained release behavior.
NL-HU had suitable uptake in MDA-MB231 cells. Cytotoxicity of NLHU
on cells was considerable. We confirmed these nanoliposomes are
potentially useful for delivery of Hydroxyurea in breast cancer cells
treatment.
Keywords :
Breast cancer , Cytotoxicity , Hydroxyurea , Nanoliposome
